Alzheimer's disease, beta-amyloidosis, and aging

Area of Science:

• Neuroscience
• Metabolic Disorders
• Genetics

Background:

• Alzheimer's disease (AD) is transitioning from a degenerative to a metabolic disorder.
• AD pathogenesis involves beta-amyloid deposition and tau protein aggregation, leading to neuronal death.
• AD is a heterogeneous disorder with familial (genetic mutations) and sporadic (multifactorial) forms.

Purpose of the Study:

• To explore the shift in understanding Alzheimer's disease (AD) as a metabolic disorder.
• To review the roles of beta-amyloid precursor protein (APP) metabolism and tau pathology in AD.
• To discuss the genetic and environmental factors contributing to familial and sporadic AD.

Main Methods:

• Review of recent discoveries in Alzheimer's disease (AD) research.
• Analysis of genetic factors, including APP gene mutations and apolipoprotein E variants.
• Examination of non-genetic risk factors such as aging, gender, and head trauma.

Main Results:

• Evidence supports AD as a metabolic disorder involving beta-amyloid and tau pathology.
• Familial AD exhibits genetic and phenotypic heterogeneity.
• Risk factors for sporadic AD include aging, gender, head trauma, and apolipoprotein E gene variants.

Conclusions:

• Understanding the molecular basis of AD, particularly amyloidogenesis, is crucial for developing targeted therapies.
• Future research aims to enable early risk prediction, treatment, and prevention of Alzheimer's disease.
• The multifactorial nature of AD necessitates a comprehensive approach to its management.